These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28608389)

  • 21. Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects.
    Karrison T
    Stat Med; 1996 Jan; 15(2):171-82. PubMed ID: 8614753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing two treatments by decision theory.
    Longford NT
    Pharm Stat; 2016 Sep; 15(5):387-95. PubMed ID: 27247139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximum likelihood estimation in survival studies under progressive interval censoring with random removals.
    Xiang L; Tse SK
    J Biopharm Stat; 2005; 15(6):981-91. PubMed ID: 16279356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frailty modeling for clustered competing risks data with missing cause of failure.
    Lee M; Ha ID; Lee Y
    Stat Methods Med Res; 2017 Feb; 26(1):356-373. PubMed ID: 25125452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Confidence interval construction for proportion difference in small-sample paired studies.
    Tang ML; Tang NS; Chan IS
    Stat Med; 2005 Dec; 24(23):3565-79. PubMed ID: 16261646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonignorable censoring in randomized clinical trials.
    Zhang J; Heitjan DF
    Clin Trials; 2005; 2(6):488-96. PubMed ID: 16422309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-sample and two-sample analysis of heterogeneous person-time data in clinical trials.
    Xu J; LaValley M
    Pharm Stat; 2012; 11(3):194-203. PubMed ID: 22344978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach.
    Rondeau V; Michiels S; Liquet B; Pignon JP
    Stat Med; 2008 May; 27(11):1894-910. PubMed ID: 18069745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing temporal agreement between central and local progression-free survival times.
    Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
    Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Weibull multi-state model for the dependence of progression-free survival and overall survival.
    Li Y; Zhang Q
    Stat Med; 2015 Jul; 34(17):2497-513. PubMed ID: 25865438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are restricted mean survival time methods especially useful for noninferiority trials?
    Freidlin B; Hu C; Korn EL
    Clin Trials; 2021 Apr; 18(2):188-196. PubMed ID: 33626896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semiparametric analysis of survival data with left truncation and dependent right censoring.
    Jiang H; Fine JP; Chappell R
    Biometrics; 2005 Jun; 61(2):567-75. PubMed ID: 16011706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropout.
    Li L; Tang S; Jiang L
    Stat Med; 2017 May; 36(10):1532-1547. PubMed ID: 28110508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A computer program for sample size and power calculations in the design of multi-arm and factorial clinical trials with survival time endpoints.
    Natarajan R; Turnbull BW; Slate EH; Clark LC
    Comput Methods Programs Biomed; 1996 Mar; 49(2):137-47. PubMed ID: 8735021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.